查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
肺部给药系统:各种技术和全球市场
市场调查报告书
商品编码
1166369

肺部给药系统:各种技术和全球市场

Pulmonary Drug Delivery Systems: Technologies and Global Markets
出版日期: | 出版商: BCC Research | 英文 148 Pages | 订单完成后即时交付

价格

全球肺部给药系统的市场规模，预计从2022年的574亿美元，2027年达到769亿美元，从2022年到2027年的预测期间中以6.0％的年复合成长率成长。

定量吸入器的部门，预计从2022年的257亿美元，2027年达到344亿美元，从2022年到2027年的预测期间中以6.0％的年复合成长率成长。还有干粉吸入剂的部门，预计从2022年的225亿美元，2027年达到306亿美元，以6.3％的年复合成长率成长。

本报告提供全球肺部给药系统的市场调查，市场概要，市场成长的各种影响因素分析，技术趋势，相关法律，市场规模的变化、预测，各种区分、各地区/主要国家的详细分析，竞争环境，主要企业简介等彙整资讯。

目录

第1章 简介

第2章 摘要、亮点

第3章 市场动态、技术的背景

  • 市场定义和概要
  • 肺的状态与治疗
  • 推动市场要素、趋势
  • 阻碍市场要素
  • 市场机会
  • 法律规章

第4章 市场明细:各肺部给药系统

  • 吸入技术概要
  • 干粉吸入剂 (DPI)
    • 概要
    • 已上市产品
  • 定量吸入器 (MDI)
    • 概要
    • 已上市产品
  • 喷雾器
    • 概要
    • 已上市产品概要:各製造商

第5章 COVID-19影响

第6章 使用中的肺部给药系统

  • 吸入治疗药
    • 类固醇
    • 支气管扩张药

第7章 市场明细:各疾病领域

  • 气喘
    • 气喘发作
    • 气喘、肥胖
    • 死亡率
    • 疾病分类
    • 诊断
    • 治疗、治疗药
    • 市场规模、预测
  • 慢性阻塞性肺病 (COPD)
    • 诊断
    • 治疗、治疗药
    • 市场规模、预测
  • 其他的病
    • 市场规模、预测

第8章 市场明细:各地区

  • 北美
  • 欧洲
  • 亚太地区
  • 其他地区
  • 南美

第9章 专利分析

第10章 企业简介

  • 3M
  • ABBOTT LABORATORIES
  • ASTRAZENECA
  • BOEHRINGER INGELHEIM GMBH
  • CIPLA
  • DR. REDDY'S LABORATORIES LTD.
  • GLAXOSMITHKLINE PLC
  • PHILIPS RESPIRONICS
  • LUPIN
  • MYLAN N.V.
  • MERCK KGAA
  • NOVARTIS AG
  • OMRON CORP.
  • PFIZER INC.
  • PULMATRIX INC.
  • TEVA PHARMACEUTICALS INDUSTRIES LTD.

第11章 附录:简称

Product Code: HLC094D

Highlights:

The global pulmonary drug delivery systems market should reach $76.9 billion by 2027 from $57.4 billion in 2022 at a compound annual growth rate (CAGR) of 6.0% for the forecast period of 2022 to 2027.

Metered dose inhalers segment of the global pulmonary drug delivery systems market is expected to grow from $25.7 billion in 2022 to $34.4 billion in 2027 at a CAGR of 6.0% for the forecast period of 2022 to 2027.

Dry powder inhalers segment of the global pulmonary drug delivery systems market is expected to grow from $22.5 billion in 2022 to $30.6 billion in 2027 at a CAGR of 6.3% for the forecast period of 2022 to 2027.

Report Scope:

This report will provide a detailed look at the pulmonary drug delivery systems market, highlighting major pulmonary diseases with detailed epidemiology for major disease areas such as asthma, COPD and cystic fibrosis. The report includes an industry-wide assessment of the novel products, launches, recent approvals, R&D pipeline and blockbuster drugs.

In the report, the regulatory scenario of pulmonary drug delivery systems is discussed for each device type. This will include products approved by regulatory authorities in recent years. Products under development or in different stages of clinical trials are also analyzed.

The report includes profiles of major companies in the market for pulmonary drug delivery systems, with overviews of their key product offerings and financials.

Report Includes:

  • 44 tables
  • A brief overview and up-to-date analysis of the global markets for pulmonary drug delivery systems
  • Analyses of the global market trends, with historic market revenue data from 2019 to 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
  • Estimation of the actual market size and revenue forecast for pulmonary drug delivery systems in USD value terms, and their corresponding market share analysis by type of drug delivery systems, application/disease area and region
  • Highlights of the major pulmonary diseases with detailed epidemiology for major disease areas such as asthma, COPD and cystic fibrosis; also, an industry-wide assessment of the key developments, novel products, recent approvals, R&D activities, pipeline products and blockbuster drugs
  • In-depth information (facts and figures) concerning market drivers, opportunities and challenges, and other macroeconomic forces affecting the global pulmonary drug delivery systems market
  • Holistic review of the international regulatory landscape for pulmonary drug delivery systems with emphasis on recently approved products as well as products under development or in different stages of clinical trials
  • Updated information on key mergers and acquisition deals, agreements, collaborations and other impactful strategies adopted by key players in the global pulmonary drug delivery systems market
  • Assessment of the recent patents published and granted on pulmonary drug delivery systems and related technologies
  • Identification of the major stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues
  • Descriptive company profiles of the market leading players, including Abbott, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline PLC, Lupin and Pfizer Inc.

Table of Contents

Chapter 1 Introduction

  • 1.1 Study Goals and Objectives
  • 1.2 Reasons for Doing This Study
  • 1.3 What's New in This Update?
  • 1.4 Scope of Report
  • 1.5 Information Sources
    • 1.5.1 Secondary Research
    • 1.5.2 Primary Research
  • 1.6 Methodology
  • 1.7 Geographic Breakdown
  • 1.8 Analyst's Credentials
  • 1.9 BCC Custom Research
  • 1.10 Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market Dynamics and Technology Background

  • 3.1 Market Definition and Overview
    • 3.1.1 Mechanism of Action
    • 3.1.2 Advantages
    • 3.1.3 Limitations/Challenges
  • 3.2 Pulmonary Conditions and Therapies
    • 3.2.1 Introduction to the Respiratory System
  • 3.3 Market Drivers and Trends
    • 3.3.1 Improved Patient Compliance and Ease of Use
    • 3.3.2 Cost Pressures on Countries
    • 3.3.3 Rising Incidence of Asthma
    • 3.3.4 Causes
    • 3.3.5 Reducing the Burden of Asthma
  • 3.4 Market Restraints
    • 3.4.1 Competition from Generics on the Rise
  • 3.5 Market Opportunities
    • 3.5.1 Introduction of Smart Nebulizers
  • 3.6 Regulation and Legislation
    • 3.6.1 U.S.

Chapter 4 Market Breakdown by Pulmonary Drug Delivery Systems

  • 4.1 Overview of Inhalation Techniques
  • 4.2 Dry Powder Inhalers (DPIs)
    • 4.2.1 Overview
    • 4.2.2 Marketed Products
  • 4.3 Metered Dose Inhalers (MDIs)
    • 4.3.1 Overview
    • 4.3.2 Marketed Products
  • 4.4 Nebulizers
    • 4.4.1 Overview
    • 4.4.2 Marketed Products Overview by Manufacturer

Chapter 5 COVID-19 Impact

  • 5.1 Overview
  • 5.2 COVID-19 Crisis
  • 5.3 Impact on Market for Pulmonary Drug Delivery Systems
  • 5.4 Current Outlook

Chapter 6 Pulmonary Drug Delivery Systems in Use

  • 6.1 Therapeutic Agents Administered via Inhalation
    • 6.1.1 Steroids
    • 6.1.2 Bronchodilators

Chapter 7 Market Breakdown by Disease Area

  • 7.1 Introduction
  • 7.2 Asthma
    • 7.2.1 Asthma Attacks
    • 7.2.2 Asthma and Obesity
    • 7.2.3 Mortality
    • 7.2.4 Disease Classification
    • 7.2.5 Diagnosis
    • 7.2.6 Treatment and Therapies
    • 7.2.7 Market Size and Forecasts
  • 7.3 Chronic Obstructive Pulmonary Disease (COPD)
    • 7.3.1 Diagnosis
    • 7.3.2 Treatment and Therapies
    • 7.3.3 Market Size and Forecasts
  • 7.4 Other Diseases
    • 7.4.1 Market Size and Forecasts

Chapter 8 Market Breakdown by Region

  • 8.1 North America
    • 8.1.1 U.S.
    • 8.1.2 Canada
    • 8.1.3 Mexico
  • 8.2 Europe
    • 8.2.1 Germany
    • 8.2.2 U.K.
    • 8.2.3 France
    • 8.2.4 Italy
    • 8.2.5 Spain
    • 8.2.6 Rest of Europe
  • 8.3 Asia-Pacific
    • 8.3.1 China
    • 8.3.2 Japan
    • 8.3.3 India
    • 8.3.4 South Korea
    • 8.3.5 Rest of Asia-Pacific
  • 8.4 Rest of the World
  • 8.5 South America

Chapter 9 Patent Analysis

  • 9.1 Overview

Chapter 10 Company Profiles

  • 3M
  • ABBOTT LABORATORIES
  • ASTRAZENECA
  • BOEHRINGER INGELHEIM GMBH
  • CIPLA
  • DR. REDDY'S LABORATORIES LTD.
  • GLAXOSMITHKLINE PLC
  • PHILIPS RESPIRONICS
  • LUPIN
  • MYLAN N.V.
  • MERCK KGAA
  • NOVARTIS AG
  • OMRON CORP.
  • PFIZER INC.
  • PULMATRIX INC.
  • TEVA PHARMACEUTICALS INDUSTRIES LTD.

Chapter 11 Appendix: Abbreviations

List of Tables

  • Summary Table A : Global Market for Pulmonary Drug Delivery Systems, by Type, Through 2027
  • Summary Table B : Global Market for Pulmonary Drug Delivery Systems, by Region, Through 2027
  • Table 1 : Key Products Going Off-Patent, 2020-2030
  • Table 2 : Inhaler Device Characteristics
  • Table 3 : Global Market for Pulmonary Drug Delivery Systems, by Type, Through 2027
  • Table 4 : Capsule-based Inhaler Devices
  • Table 5 : Blister-based Inhaler Devices
  • Table 6 : Reservoir/Cartridge-based Inhaler Devices
  • Table 7 : MDIs, HFA Propellant
  • Table 8 : MDIs, Anti-Inflammatory Medicine
  • Table 9 : MDIs, Combination Medicine
  • Table 10 : Commonly Used MDIs
  • Table 11 : Comparison of Nebulizers
  • Table 12 : Marketed Nebulizers by Manufacturer
  • Table 13 : Total Number of COVID-19 Confirmed Cases and Deaths, by Region, June 2022
  • Table 14 : COVID-19 Confirmed Cases and Deaths Globally, by Country, June 20, 2022
  • Table 15 : Inhaled Steroids
  • Table 16 : Inhaled Corticosteroids
  • Table 17 : Inhaled Corticosteroids, Combination Inhalers
  • Table 18 : Short-Acting Inhaled Beta-Agonist (SABA) Bronchodilators
  • Table 19 : Short-Acting Inhaled Muscarinic Antagonist (SAMA) and SABA Combination Bronchodilators
  • Table 20 : Long-Acting Inhaled Beta-2 Agonists (LABA) Bronchodilators
  • Table 21 : Long-Acting Inhaled Muscarinic Antagonists (LAMA) Bronchodilators
  • Table 22 : LABA and LAMA Combination Bronchodilators
  • Table 23 : Global Asthma Market, Through 2027
  • Table 24 : Leading Causes of Death Worldwide, 2020
  • Table 25 : Global COPD Market, Through 2027
  • Table 26 : Global Market for Other Pulmonary Diseases, Through 2022
  • Table 27 : Prevalence of Asthma, by Race and Ethnicity in Americans
  • Table 28 : European Self-Reported Asthma, 2020
  • Table 29 : European Self-Reported COPD, 2020
  • Table 30 : Leading Causes of Death in Australia, 2020 and 2021
  • Table 31 : Key Patents, Pulmonary Drug Delivery Systems
  • Table 32 : 3M: Key Developments
  • Table 33 : Abbott: Product Portfolio by Business Segment, 2021
  • Table 34 : Abbott: Key Developments
  • Table 35 : AstraZeneca PLC: Key Developments
  • Table 36 : Royal Philips: List of Subsidiaries
  • Table 37 : Philips Health: Business Segments
  • Table 38 : Lupin: Key Developments
  • Table 39 : Novartis AG: Key Developments
  • Table 40 : Pfizer Inc.: Key Developments
  • Table 41 : Teva: Key Developments
  • Table 42 : Abbreviations Used in Pulmonary Drug Delivery Systems

List of Figures

  • Summary Figure : Global Market for Pulmonary Drug Delivery Systems, by Type, 2019-2027
  • Figure 1 : Smoking in Adults, by Region, 2020
  • Figure 2 : Global Market for Pulmonary Drug Delivery Systems, by Type, 2019-2027
  • Figure 3 : Non-Communicable Disease Mortality Share, by Cause of Death, 2021
  • Figure 4 : Global Asthma Market, 2019-2027
  • Figure 5 : Global COPD Market, 2019-2027
  • Figure 6 : Global Market for Other Pulmonary Diseases, 2019-2027
  • Figure 7 : North American Pulmonary Drug Delivery Systems Market, 2019-2027
  • Figure 8 : Health Issues in the Mexican Population, Proportional Mortality, 2020
  • Figure 9 : Annual Mortality Rate for Asthma, by Country, 2020
  • Figure 10 : European Pulmonary Drug Delivery Systems Market, 2019-2027
  • Figure 11 : U.K. Mortality, by Disease 2021
  • Figure 12 : Leading Causes of Death in Italy, Percentage Change, 2020
  • Figure 13 : Leading Causes of Death in Rest of Europe Region, 2021
  • Figure 14 : Asia-Pacific Pulmonary Drug Delivery Systems Market, 2019-2027
  • Figure 15 : Annual Mortality Rates in Middle East and Africa, by Disease, 2020
  • Figure 16 : Rest of the World Pulmonary Drug Delivery Systems Market, 2019-2027
  • Figure 17 : Abbott: Annual Revenue, 2018-2021
  • Figure 18 : Abbott: Revenue Share, by Segment, 2021
  • Figure 19 : AstraZeneca PLC: Annual Revenue, 2018-2020
  • Figure 20 : AstraZeneca PLC: Revenue Share, by Therapy Areas, 2020
  • Figure 21 : Dr. Reddy's Laboratories Ltd.: Annual Revenue, 2018-2020
  • Figure 22 : Dr. Reddy's Laboratories Ltd.: Revenue Share, by Business Segment, 2020
  • Figure 23 : GlaxoSmithKline PLC: Annual Revenue, 2018-2020
  • Figure 24 : GlaxoSmithKline PLC: Revenue Share, by Business Segment, 2020
  • Figure 25 : Lupin: Annual Revenue, 2018-2020
  • Figure 26 : Merck KGaA: Annual Revenue, 2018-2020
  • Figure 27 : Merck KGaA: Revenue Share, by Business Segment, 2020
  • Figure 28 : Novartis AG: Annual Revenue, 2018-2020
  • Figure 29 : Novartis AG: Revenue Share, by Division, 2020
  • Figure 30 : Pfizer Inc.: Annual Revenue, 2018-2020
  • Figure 31 : Teva: Annual Revenue, 2018-2020